ÐÂÎÅÖÐÐÄ
News Center
ÖÎÁÆ°ß¿é×´Òøм²¡£¡£¡£¡£¡£¡£¡bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾TQH3906¶þÆÚÁÙ´²µÖ´ïÑо¿Ö÷ÒªÖÕµã
Ðû²¼Ê±¼ä£º2025-12-29
12ÔÂ29ÈÕ £¬£¬£¬ £¬£¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾£¨1177.HK£©Ðû²¼ £¬£¬£¬ £¬£¬£¬£¬£¬Õý´óÌìÇç×ÔÖ÷Ñз¢µÄ1ÀàÁ¢ÒìÒ©TQH3906£¨TYK2/JAK1 JH2±ä¹¹ÒÖÖƼÁ£©ÓÃÓÚÖÐÖضȰ߿é×´Òøм²¡£¡£¡£¡£¡£¡£¨PsO£©µÄ¶þÆÚÁÙ´²ÊÔÑé £¬£¬£¬ £¬£¬£¬£¬£¬µÖ´ïÖ÷ÒªÑо¿Öյ㡣¡£¡£¡£¡£¡£Ñо¿Ð§¹ûÏÔʾ £¬£¬£¬ £¬£¬£¬£¬£¬ÔÚ¶þÆÚÍƼö¼ÁÁ¿£¨RP2D£©ÖÎÁÆ12ÖÜʱ £¬£¬£¬ £¬£¬£¬£¬£¬PASI 75£¨Òøм²¡Ãæ»ýºÍÑÏÖØˮƽÆÀ·Ö½Ï»ùÏßϽµÖÁÉÙ75%£©Ó¦´ðÂÊÁè¼Ý90% £¬£¬£¬ £¬£¬£¬£¬£¬PASI 90£¨Òøм²¡Ãæ»ýºÍÑÏÖØˮƽÆÀ·Ö½Ï»ùÏßϽµÖÁÉÙ90%£©Ó¦´ðÂÊÁè¼Ý70% £¬£¬£¬ £¬£¬£¬£¬£¬²¢ÇÒËùÓмÁÁ¿×éÌåÏÖ³öÓÅÒìµÄÇå¾²ÐÔÓëÄÍÊÜÐÔ¡£¡£¡£¡£¡£¡£
.jpg/output%20(1)__600x400.jpg)
PASI 75Ó¦´ðÂʳ¬90%¡¢PASI 90Ó¦´ðÂʳ¬70%
¸ÃÑо¿ÊÇÒ»ÏîËæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕÕ¡¢¶àÖÐÐĵĶþÆÚÁÙ´²ÊÔÑ飨NCT06542614£© £¬£¬£¬ £¬£¬£¬£¬£¬ÓÉÖйúÒ½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½ÔºÐË·Ü»ª½ÌÊÚǣͷ £¬£¬£¬ £¬£¬£¬£¬£¬Ö¼ÔÚÆÀ¼ÛTQH3906ÔÚÖÐÖضȰ߿é×´Òøм²¡ÊÜÊÔÕßÖеÄÓÐÓÃÐÔºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£±¾Ñо¿×îÖÕÈë×é209Àý»¼Õß £¬£¬£¬ £¬£¬£¬£¬£¬°üÀ¨Î¿½å¼Á×éºÍ5¸ö²î±ðµÄTQH3906¼ÁÁ¿×é £¬£¬£¬ £¬£¬£¬£¬£¬½ÓÄÉÌìÌìÒ»´Î¿Ú·þ¸øÒ©·½·¨¡£¡£¡£¡£¡£¡£
ÁÙ´²ÁÆЧ·½Ãæ £¬£¬£¬ £¬£¬£¬£¬£¬TQH3906ÌåÏÖ³öÓÅÒìµÄ¼ÁÁ¿-ЧӦ¹Øϵ £¬£¬£¬ £¬£¬£¬£¬£¬²¢ÔÚÖ÷ÒªÖÕµãÉÏ̽Ë÷µ½Ò©Ð§µÄƽ̨ÆÚ¡£¡£¡£¡£¡£¡£ÔÚÔ¤ÆÚµÄRP2D¼ÁÁ¿ÏÂÖÎÁÆ12ÖÜʱ £¬£¬£¬ £¬£¬£¬£¬£¬Áè¼Ý90%ÊÜÊÔÕßµÖ´ïPASI 75¡¢Áè¼Ý70%ÊÜÊÔÕßµÖ´ïPASI 90 £¬£¬£¬ £¬£¬£¬£¬£¬ÁÙ´²»ñÒæÓëÉúÎïÖƼÁIL-17/IL-23ÒÖÖƼÁÏ൱ £¬£¬£¬ £¬£¬£¬£¬£¬Ïà±ÈÓÚÆäËûÒÑÉÏÊеÄÒøм²¡¿Ú·þÖƼÁ»ñÒæÏÔ×Å¡£¡£¡£¡£¡£¡£
Çå¾²ÐÔЧ¹ûÏÔʾ £¬£¬£¬ £¬£¬£¬£¬£¬TQH3906ÕûÌåÇå¾²ÐÔÓÅÒì £¬£¬£¬ £¬£¬£¬£¬£¬×ÜÌå²»Á¼·´Ó¦±¬·¢ÂÊÓëο½å¼Á×éÏ൱ £¬£¬£¬ £¬£¬£¬£¬£¬Ö÷ÒªÖÎÁÆÏà¹Ø²»Á¼ÊÂÎñ£¨TEAE£©Îª1-2¼¶ £¬£¬£¬ £¬£¬£¬£¬£¬ÓëͬÀàTYK2ÒÖÖƼÁÇå¾²ÐÔÌØÕ÷ÏàÀàËÆ £¬£¬£¬ £¬£¬£¬£¬£¬Î´ÊӲ쵽зºÆðµÄÇå¾²ÐÔÐźš£¡£¡£¡£¡£¡£±¾Ñо¿ÏêϸµÄÑо¿Ð§¹û½«ÔÚºóÐø¿ªÕ¹µÄ¹ú¼ÊѧÊõ¾Û»áÉÏÐû²¼¡£¡£¡£¡£¡£¡£
°ÐÏòJH2½á¹¹Óò £¬£¬£¬ £¬£¬£¬£¬£¬¼æ¹Ë¸ßÑ¡ÔñÐÔÓëÇå¾²ÐÔ
TQH3906ͨ¹ý°ÐÏòTYK2/JAK1µÄ¼Ù¼¤Ã¸Óò£¨JH2£©Ê©Õ¹×÷Óà £¬£¬£¬ £¬£¬£¬£¬£¬Ïà½ÏÓÚ¼ÈÍù°ÐÏò»îÐÔ¼¤Ã¸Óò£¨JH1£©µÄJAKÒÖÖƼÁ £¬£¬£¬ £¬£¬£¬£¬£¬¿ÉÒÔÓÐÓõØά³Ö¶ÔJAK2¡¢JAK3ÓëÆäËû¼¤Ã¸µÄ¸ß¶ÈÑ¡ÔñÐÔ £¬£¬£¬ £¬£¬£¬£¬£¬´Ó¶øïÔ̶ԷǰбêÂÑ°×µÄDZÔÚÒÖÖÆ×÷Óᣡ£¡£¡£¡£¡£ÕâÖÖ¸ßÑ¡ÔñÐÔ¿ÉÒÔÌá¸ßÖÎÁÆЧ¹û²¢½µµÍ¸±×÷Óà £¬£¬£¬ £¬£¬£¬£¬£¬Õ¹ÏÖ³öÖ÷ÒªµÄÖÎÁÆDZÁ¦¡£¡£¡£¡£¡£¡£³ý°ß¿é×´Òøм²¡Íâ £¬£¬£¬ £¬£¬£¬£¬£¬TQH3906½«¼ÌÐø¿ªÕ¹°üÀ¨Ñ×Ö¢ÐÔ³¦²¡¡¢Òøм²¡ÊàŦÑ׵ȶà¸ö×ÔÃ⡢Ƥ·ôÁìÓòÐÂ˳Ӧ֢µÄ̽Ë÷Ñо¿¡£¡£¡£¡£¡£¡£
Òøм²¡ÊÇÒ»ÖÖÓÉÒÅ´«¡¢ÃâÒß¼°ÇéÐÎÒòËØÅäÏàÖúÓõÄÂýÐÔÑ×Ö¢ÐÔƤ·ô²¡ £¬£¬£¬ £¬£¬£¬£¬£¬È«ÇòÔ¼2%-3%ÈËȺÊÜÆäÓ°Ïì £¬£¬£¬ £¬£¬£¬£¬£¬×î³£¼ûµÄÒøм²¡ÀàÐÍΪ°ß¿é×´Òøм²¡ £¬£¬£¬ £¬£¬£¬£¬£¬Ô¼Õ¼ËùÓÐÒøм²¡»¼ÕßµÄ80%-90%[1] £¬£¬£¬ £¬£¬£¬£¬£¬ÆäÖÐ30%-40%Ï£ÍûΪÖÐÖضÈ[2]¡£¡£¡£¡£¡£¡£ËäÈ»Òøм²¡Í¨³£ÌåÏÖΪƤ·ôÑ×ÐÔ°ß¿é £¬£¬£¬ £¬£¬£¬£¬£¬µ«Ô½À´Ô½¶àµÄÖ¤¾ÝÅú×¢ £¬£¬£¬ £¬£¬£¬£¬£¬Òøм²¡ÊÇÒ»ÖÖ°éÓжàÖÖ¹²´æ¼²²¡µÄ¶àϵͳÂýÐÔÑ×Ö¢ÐÔ¼²²¡ £¬£¬£¬ £¬£¬£¬£¬£¬°üÀ¨£º·ÊÅÖ¡¢´úл×ÛºÏÕ÷¡¢ÐÄÄÔѪ¹Ü¼²²¡¡¢×ÔÉíÃâÒßÐÔ¼²²¡µÈ¡£¡£¡£¡£¡£¡£Òøм²¡Òò²¡ÇéÖظ´¡¢Öð½¥¼ÓÖØ¡¢Ò©Îï²»Á¼·´Ó¦¼°ºÏ²¢Ö¢µÈÒòËØ £¬£¬£¬ £¬£¬£¬£¬£¬ÑÏÖØÓ°Ï컼ÕßÉúÑÄÖÊÁ¿¡£¡£¡£¡£¡£¡£
¹Å°åϵͳÖÎÁÆÒ©ÎÈç¼×°±µûßÊ¡¢»·æßËØÀࣩËä¿É¶ÌÆÚ¿ØÖÆÖ¢×´ £¬£¬£¬ £¬£¬£¬£¬£¬µ«±£´æ¸Î¶¾ÐÔ¡¢¹ÇËèÒÖÖƵȼÁÁ¿ÒÀÀµÐÔΣº¦[3]¡£¡£¡£¡£¡£¡£ÉúÎïÖƼÁ£¨ÈçTNF-α¡¢IL-17/IL-23ÒÖÖƼÁ£©ÏÔÖøÌáÉýÁËÁÆЧ £¬£¬£¬ £¬£¬£¬£¬£¬µ«Ðèºã¾Ã×¢Éä¸øÒ©¼°Ç±ÔÚѬȾΣº¦ÏÞÖÆÁËÁÙ´²Ó¦ÓÃ[4]¡£¡£¡£¡£¡£¡£½üÄêÀ´ £¬£¬£¬ £¬£¬£¬£¬£¬»ùÓÚÒøм²¡·Ö×Ó»úÖÆÑо¿µÄÍ»ÆÆ £¬£¬£¬ £¬£¬£¬£¬£¬¿Ú·þС·Ö×Ó°ÐÏòÒ©ÎïÒò¾«×¼×è¶Ï¡¢¸øÒ©±ã½Ý¡¢ÄÍÊÜÐԺõÈÓÅÊÆ £¬£¬£¬ £¬£¬£¬£¬£¬³ÉΪÑо¿ÈÈÃÅ¡£¡£¡£¡£¡£¡£
ÏÖÔÚ £¬£¬£¬ £¬£¬£¬£¬£¬º£ÄÚ»ñÅúµÄÖÎÁÆ°ß¿é×´Òøм²¡µÄ¿Ú·þС·Ö×Ó°ÐÏòÒ©°üÀ¨PDE-4ÒÖÖƼÁÓëTYK2 JH2±ä¹¹ÒÖÖƼÁ £¬£¬£¬ £¬£¬£¬£¬£¬ÆäÈ«Çò¶àÖÐÐÄ×¢²áÑо¿Ð§¹ûÏÔʾ16ÖÜPASI 75Ó¦´ðÂÊ¿¿½ü60%¡¢PASI 90Ó¦´ðÂÊ¿¿½ü40%[5-7] £¬£¬£¬ £¬£¬£¬£¬£¬ÁÙ´²ÐèÇóÁÆЧ¸ü¸ßÇÒÇå¾²ÐԿɿصÄС·Ö×Ó°ÐÏòÒ©¡£¡£¡£¡£¡£¡£TQH3906»ùÓڴ˴΢òÆÚÁÙ´²Õ¹ÏÖµÄÓÅÒìÊý¾ÝÓëÓÅÒìÇå¾²ÐÔ £¬£¬£¬ £¬£¬£¬£¬£¬ÓÐÍûΪÒøм²¡»¼ÕßÌṩһ¸öÓÃÒ©±ã½Ý¡¢ÁÆЧȷÇС¢Çå¾²ÐÔÓÅÒìµÄÖÎÁÆÐÂÑ¡Ôñ¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
[1] ÖлªÒ½Ñ§»áƤ·ôÐÔ²¡Ñ§·Ö»áÒøм²¡×¨ÒµÎ¯Ô±»á.ÖйúÒøм²¡ÕïÁÆÖ¸ÄÏ£¨2023°æ£©[J].ÖлªÆ¤·ô¿ÆÔÓÖ¾,2023,56(7):573-625.
[2] Korman NJ. Management of psoriasis as a systemic disease: what is the evidence?[J]. Br J Dermatol,2020,182(4):840-848.
[3] Bochncke WH, Brembilla NC. Unmet needs in the field of psoriasis: pathogenesis and treatment[J].Clin Rev Allergy Immunol, 2018, 55(3): 295-311.
[4] ÖлªÒ½Ñ§»áƤ·ôÐÔ²¡Ñ§·Ö»áÒøм²¡×¨ÒµÎ¯Ô±»á.Òøм²¡ÉúÎïÖƼÁ´ï±êÖÎÁÆר¼Ò¹²Ê¶[J].ÖлªÆ¤·ô¿ÆÔÓÖ¾ £¬£¬£¬ £¬£¬£¬£¬£¬2023,56(3):191-203.
[5] Armstrong AW, Gooderham M, Warren RB,et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39.
[6] Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 Jan;88(1):40-51.
[7] Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul;73(1):37-49.
ÉùÃ÷£º
1.ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷ £¬£¬£¬ £¬£¬£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ £¬£¬£¬ £¬£¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£
2.±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£¡£
3.±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼ £¬£¬£¬ £¬£¬£¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼ £¬£¬£¬ £¬£¬£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢ £¬£¬£¬ £¬£¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö £¬£¬£¬ £¬£¬£¬£¬£¬°üÀ¨Óйء¾TQH3906¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ £¬£¬£¬ £¬£¬£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö £¬£¬£¬ £¬£¬£¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû £¬£¬£¬ £¬£¬£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ïì £¬£¬£¬ £¬£¬£¬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦ £¬£¬£¬ £¬£¬£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö £¬£¬£¬ £¬£¬£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇó £¬£¬£¬ £¬£¬£¬£¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£¡£